PCSK9 and chronic kidney disease: The largest published clinical trial on PCSK9 inhibitors in CKD patients was the FOURIER trial by Charytan et al. in 2019, which had 27,565 participants who were administered evolocumab 140 mg bi-weekly or 420 mg monthly; they were randomly given evolocumab or a placebo in a 1:1 ratio while all being on background statins [7].